BridgeMD
New treatment option for Benign Prostatic Hyperplasia
Official title A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate
ClinicalTrials.gov ID: NCT07357324
What this study is testing
What is Tamsulosin Hydrochloride Sustained-Release Capsules?
Tamsulosin Hydrochloride Sustained-Release Capsules is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for benign prostatic hyperplasia.
Also referred to as Tamsulosin, α1-adrenergic receptor antagonist.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study will test whether a traditional Chinese medicine called Lingze tablets, when added to the standard drug tamsulosin, can better improve sleep and nighttime urination problems in men after prostate surgery. Who can participate?
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older, men only
You may be able to join if
- Male patients aged 50 years or older
- History of transurethral holmium laser enucleation of the prostate (HoLEP)
- Nocturia frequency ≥2 times per night
- Documented bladder outlet obstruction
- Presence of postoperative urinary incontinence and urgency symptoms
You likely can't join if
- Known hypersensitivity or intolerance to tamsulosin hydrochloride, Lingze tablets, or any component of these medications
- Active malignancy or severe cancer requiring treatment
- Cognitive impairment, psychiatric disorder, or language barrier that prevents understanding of study requirements or completion of questionnaires
- Severe multi-organ failure or dysfunction that would interfere with study participation
- Previous enrollment in conflicting clinical trials within the past 30 days
- Inability to comply with the medication regimen or study protocol
See the full eligibility criteria
- Male patients aged 50 years or older
- History of transurethral holmium laser enucleation of the prostate (HoLEP)
- Nocturia frequency ≥2 times per night
- Documented bladder outlet obstruction
- Presence of postoperative urinary incontinence and urgency symptoms
- Ability to understand study procedures and provide written informed consent
- Willingness to complete all scheduled follow-up visits and assessments
- Known hypersensitivity or intolerance to tamsulosin hydrochloride, Lingze tablets, or any component of these medications
- Active malignancy or severe cancer requiring treatment
- Cognitive impairment, psychiatric disorder, or language barrier that prevents understanding of study requirements or completion of questionnaires
- Severe multi-organ failure or dysfunction that would interfere with study participation
- Previous enrollment in conflicting clinical trials within the past 30 days
- Inability to comply with the medication regimen or study protocol
The study team makes the final eligibility decision.
Where it's taking place
- Yiwu, Zhejiang, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Yiwu, Zhejiang, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.